SEARCH

SEARCH BY CITATION

References

  • 1
    UNODC 2007. United Nations Office on Drugs and Crime. World Drug Report. New York: United Nation, 2007.
  • 2
    Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94: 221229.
  • 3
    Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 2002; 97: 13831394.
  • 4
    Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas 1994–2002. Drug Alcohol Depend 2005; 78: 7381.
  • 5
    Passini S. The delinquency-drug relationship: the influence of social reputation and moral disengagement. Addict Behav 2012; 37: 577579.
  • 6
    Hall W. The contribution of research to Australian policy responses to heroin dependence 1990–2001: a personal retrospection. Addiction 2004; 99: 560569.
  • 7
    Newman RG. Methadone treatment; defining and evaluating success. N Engl J Med 1987; 317: 447450.
  • 8
    Hser Y, Hoffman V, Grella C, Anglin MD. A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry 2001; 58: 503508.
  • 9
    Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2007; 103: 8088.
  • 10
    Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98: 673684.
  • 11
    Milby JB. Methadone maintenance to abstinence: how many make it? J Nerv Ment Dis 1988; 176: 409422.
  • 12
    Beynon CM, Bellis M, McVeigh J. Trends in drop out, drug free discharge and rates of re-presentation: a retrospective cohort study of drug treatment clients in the North West of England. BMC Public Health 2006; 6: 205. doi: 10.1186/1471-2458-6-205.
  • 13
    Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990–2002. Drug Alcohol Depend 2006; 81: 5561.
  • 14
    McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 2005; 100: 447458.
  • 15
    Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255264.
  • 16
    Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; (3): CD002209.
  • 17
    Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opiopid maintenance treatment (OMT); a national, prospective cross-registry study. Drug Alcohol Depend 2008; 94: 151157.
  • 18
    Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor AD, Angelis D, Cameron S, Parry J, Lyons M, Goldberg D, Allen E, Hickman M. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 19781988.
  • 19
    Moffatt S, Weatherburn D, Donnelly N. What Caused the Recent Drop in Property Crime? Crime and Justice Bulletin 85. Sydney, NSW: NSW Bureau of Crime Statistics and Research, 2005.
  • 20
    De Maeyer J, Vanderplasschen W, Camfield L, Vanheule S, Sabbe B, Broekaert E. A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals. Int J Nurs Stud 2011; 48: 12441257.
  • 21
    D'Aunno T, Vaughan TE. Variation in methadone treatment practices: results from a national study. J Am Med Assoc 1992; 267: 253258.
  • 22
    Barnett PG, Trafton JA, Humphreys K. The cost of concordance with opiate substitution treatment guidelines. J Subst Abuse Treat 2010; 39: 141149.
  • 23
    Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 2006; 26: 58945900.
  • 24
    Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65: 685694.
  • 25
    Nilsson M-I, Grondblah L, Widerlov E, Anggard E. Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. Eur J Clin Pharmacol 1983; 25: 497501.
  • 26
    Elkader AK, Brands B, Dunn E, Selby P, Sproule BA. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J Clin Psychopharmacol 2009; 29: 1.
  • 27
    Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi A, Bochner F, White JM. 2004) Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br J Clin Pharmacol 2004; 58: 609617.
  • 28
    Brunen S, Vincent PD, Baumann P, Hiemke C, Havemann-Reinecke U. Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 2011; 33: 5.
  • 29
    Martin WR, Jasinski JR, Haertzen CA, Kay DC, Jones B, Mansky PA, Carpenter RW. Methadone – a reevaluation. Arch Gen Psychiatry 1973; 28: 286295.
  • 30
    Volavka J, Verebely K, Resnick R, Mule S. Methadone dose, plasma level, and cross-tolerance to heroin in man. J Nerv Ment Dis 1978; 166: 104109.
  • 31
    Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; (3): CD002208. doi: 10.1002/14651858.CD002208.
  • 32
    Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104: 11931200.
  • 33
    Van Den Brink W, Hendriks VM, Blanken P, Koeter MWJ, Van Zwieten BJ, Van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Br Med J 2003; 327: 310312.
  • 34
    Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361: 777786.
  • 35
    Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Groshkova T, Charles V, Martin A, Farzisi L. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 18851895.
  • 36
    Perneger TV, Giner F, Del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. Br Med J 1998; 317: 1318.
  • 37
    Naber D, Haassen C. The German Model Project for Heroin-Assisted Treatment of Opioid Dependent Patients – A Multi Site, Randomised Controlled Treatment Study. Hamburg: Centre for Interdisciplinary addiction Research of Hamburg University, 2006.
  • 38
    Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2010; (8): CD003410. doi: 10.1002/14651858.CD003410.pub3.
  • 39
    Reuter P. Can heroin maintenance help Baltimore? The Abell Foundation, 111 S. Calvert Street, Suite 2300, Baltimore, Maryland 21202, 2009.
  • 40
    Jasinski DR, Pevnick JS, Griffiths JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978; 35: 501516.
  • 41
    Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70: S13S27.
  • 42
    Bell J, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104: 7377.
  • 43
    Mattick RP, Kimber J, Breen C, Davoli M. 2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence The Cochrane Library.
  • 44
    Mattick RP, Ali R, White J, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441452.
  • 45
    Lopatko OV, White JM, Huber A, Ling W. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend 2003; 69: 317322.
  • 46
    Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, Nilsson LH, Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007; 164: 797803.
  • 47
    Bell J, Shanahan M, Mutch C, Rea F, Ryan A, Batey R, Dunlop A, Winstock A. A randomised trial of effectiveness and cost effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007; 102: 18991907.
  • 48
    Ruger JP, Chawarski M, Mazlan M, Luekens C, Ng N, Schottenfeld R. Costs of addressing heroin addiction in Malaysia and 32 comparable countries worldwide. Health Serv Res 2102; 47: 865887.
  • 49
    Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993–2008): analyses using OD4 index in England and Scotland. BMJ 2010b; 341: c4851. doi: 10.1136/bmj.c4851.
  • 50
    Degenhardt L, Larance B, Bell J, Winstock A, Lintzeris N, Ali R, Scheuer N, Mattick R. Injection of OST in Australia following the introduction of a mixed partial agonist-antagonist opioid medication. Med J Aust 2009; 191: 161165.
  • 51
    Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of Psychostimulant Drugs for Cocaine Dependence. Cochrane Database Syst Rev 2010; (2): CD007380. doi: 10.1002/14651858.CD007380.pub3.
  • 52
    Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence. Br J Psychiatry 2000; 176: 285289.
  • 53
    Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011; (10): CD004147. doi: 10.1002/14651858.CD004147.pub4.
  • 54
    Jaffe J, O'Keeffe C. From morphine clinics to buprenorphine; regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003; 70: S3S11.
  • 55
    D'Aunno T, Vaughan TE. Variations in methadone treatment practices: results from a national study. J Am Med Assoc 1992; 267: 253258.
  • 56
    Strang J, Manning V, Mayet S, Ridge G, Best D, Sheridan J. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England 1995–2005. Addiction 2007; 102: 761770.
  • 57
    Marsden J, Eastwood B, Bradbury C, Dale-Perera A, Farrell M, Hammond P, Knight J, Randhawa K, Wright C. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 2009; 374: 12621270.
  • 58
    Department of Health (England) and the devolved administrations. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, 2007.
  • 59
    Goldstein A, Judson BA. Critique. In: Research into the Treatment of Narcotic Addiction – State of the Art, eds Cooper JR , Altman F , Brown BS , Czechowicz D . Washington DC: National Institute on Drug Abuse, 1983; 8091.
  • 60
    Connell PH. Drug dependence in great britain: a challenge to the practice of medicine. In: Scientific Basis of Drug Dependence, ed. Steinberg H . Livingstone: Churchill London, 1969; 291299.
  • 61
    Dole VP, Nyswander M. 1973. Rehabilitation of patients on methadone programs. Proceedings of the 5th National Conference on Methadone Treatment, 1–7. New York: National Association for the Prevention of Addiction to Narcotics.
  • 62
    HM Government. Drug Strategy 2010: Reducing Demand, Restricting Supply, Building Recovery: Supporting People to Live A Drug Free Life. London: HM Government, 2010.
  • 63
    Hunt DA, Lipton DS, Goldsmith DS, Strug DL, Spunt B. ‘It takes your heart’: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict 1985–86; 20: (11&12): 17511771.
  • 64
    Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000; 22: 179190.
  • 65
    Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services and Outcome. New York: Springer-Verlag, 1991.
  • 66
    Moos RH. Addictive disorders in context: principles and puzzles of effective treatment and recovery. Psychol Addict Behav 2003; 17: 312.
  • 67
    Wampold BE. The Great Psychotherapy Debate: Models, Methods, and Findings. Mahwah NJ: Lawrence Erlbaum Associates Inc, 2001.
  • 68
    Center for Substance Abuse Treatment. Methadone-Associated Mortality: Report of A National Assessment, May 8–9, 2003. CSAT Publication No. 28-03. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2004.
  • 69
    Henry-Edwards S, Gowing L, White J, Ali R, Bell J, Brough R, Lintzeris N, Ritter A, Quigley A. Clinical Guidelines and Procedures for the Use of Methadone in the Maintenance Treatment of Heroin Dependence. Canberra, ACT: Department of Health and Aged Care, 2002.
  • 70
    Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988; 319: 13181330.
  • 71
    Murray RP, Bailey WC, Daniels K, Bjornson WM, Kurnow K, Connett JE, Nides MA, Kiley JP. Safety of nicotine polacrilex gum used by 3094 participants in the Lung Health Study. Chest 1996; 109: 438445.
  • 72
    Rodu B. The scientific foundation for tobacco harm reduction, 2006–2011. Harm Reduct J 2011; 8: 19. doi: 10.1186/1477-7517-8-19.
  • 73
    Ramström LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control 2006; 15: 210214. doi: 10.1136/tc.2005.014969.
  • 74
    Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006; 15: 280285.